Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ADMA Biologics, Inc. is a U.S.-based specialty biopharmaceutical company focused on the development, manufacturing, and commercialization of plasma-derived biologics. The company operates within the biopharmaceuticals and plasma-derived therapeutics industries, with a primary emphasis on treatments for immune-compromised patient populations. ADMA’s core products are immune globulin therapies used in the treatment of primary humoral immunodeficiency and for the prevention of hepatitis B recurrence following liver transplantation.
The company’s primary revenue drivers are its FDA-approved immune globulin products, ASCENIV, BIVIGAM, and Nabi-HB, all of which are derived from human plasma. ADMA serves hospitals, specialty pharmacies, and healthcare providers in the United States, positioning itself as a vertically integrated operator that controls plasma collection, manufacturing, and commercial distribution. Founded in 2004, ADMA Biologics evolved from a development-stage entity into a commercial-stage company following FDA approvals of its products between 2017 and 2019 and subsequent scaling of plasma collection and manufacturing infrastructure.
Business Operations
ADMA Biologics operates through two integrated business components: plasma collection and plasma-derived product manufacturing and sales. Its plasma collection operations are conducted through wholly owned subsidiaries, including ADMA BioCenters Georgia Inc. and ADMA BioCenters Texas Inc., which supply plasma used in its manufacturing process. This vertical integration is a central element of ADMA’s operating model and is designed to enhance supply reliability and cost control.
Manufacturing and product commercialization are conducted through ADMA’s FDA-licensed manufacturing facility in Boca Raton, Florida, where the company produces its immune globulin therapies. Revenue is generated primarily from domestic sales of ASCENIV, BIVIGAM, and Nabi-HB in the U.S. market. ADMA does not currently report material international product sales, and its operations are concentrated in regulated U.S. healthcare channels.
Strategic Position & Investments
ADMA’s strategic direction centers on expanding plasma collection capacity, increasing manufacturing throughput, and driving commercial adoption of its differentiated immune globulin products. A key strategic advantage is its vertically integrated plasma-to-product model, which allows for greater control over raw material supply in a plasma-constrained market. The company has made sustained capital investments in expanding and upgrading its plasma collection centers and manufacturing capabilities to support long-term growth.
ADMA has not pursued large-scale acquisitions in recent years but has invested heavily in internal infrastructure, including facility expansions and process optimization initiatives. The company’s product ASCENIV is positioned as a premium, high-titer immune globulin with differentiated antibody profiles, reflecting ADMA’s focus on specialized and higher-margin segments of the immune globulin market. Emerging areas of focus include operational efficiency, margin expansion, and increased utilization of internally sourced plasma.
Geographic Footprint
ADMA Biologics’ operations are primarily concentrated in the United States, where it maintains its corporate headquarters in Ramsey, New Jersey. Plasma collection centers are located across multiple U.S. states, including Georgia and Texas, while manufacturing operations are centralized in Florida. The company’s commercial activities are focused on U.S. healthcare providers and institutions.
While ADMA does not currently maintain significant direct operations outside the U.S., its products contribute to the broader North American plasma therapeutics market. International expansion is not a material component of current operations based on available public disclosures, and data regarding near-term non-U.S. commercialization plans is inconclusive based on available public sources.
Leadership & Governance
ADMA Biologics was founded by Adam S. Grossman, who continues to lead the company with a strategic focus on disciplined growth, vertical integration, and long-term value creation in the plasma therapeutics market. The leadership team emphasizes operational control, regulatory compliance, and capital-efficient expansion as core elements of its governance philosophy.
Key members of the executive leadership team include:
- Adam S. Grossman – President and Chief Executive Officer
- Brian Lenz – Chief Financial Officer
Additional executive leadership and board-level governance details are disclosed in SEC filings, including Form 10-K and DEF 14A, though certain role-specific responsibilities beyond the executives listed above are not consistently detailed across public sources.